Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.64 |
| ▸ | BRAF | P15056 | 4/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.58 |
| ▸ | RAF1 | P04049 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.58 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.58 |
| ▸ | NEK2 | P51955 | 2/20 | 0.58 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.58 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.58 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.58 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.58 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.58 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.58 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.58 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.58 |
| ▸ | PLK4 | O00444 | 1/20 | 0.58 |
| ▸ | PIR | O00625 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL297226 | 1.00 | CYP3A4 (0.71) | CYP3A4CYP2C9CYP2C19BRAFRIPK2 | |
| SCHEMBL15666917 | 0.94 | BRAF (0.72) | CYP3A4CYP2C9CYP2C19BRAFRIPK2 | |
| SCHEMBL298288 | 0.91 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19BRAFRIPK2 | |
| SCHEMBL298200 | 0.91 | CYP3A4 (0.73) | CYP3A4CYP2C9CYP2C19BRAFRIPK2 | |
| SCHEMBL7877605 | 0.89 | CYP2C19 (0.74) | CYP3A4CYP2C9CYP2C19BRAFRIPK2 | |
| SCHEMBL299621 | 0.88 | CYP3A4 (0.70) | CYP3A4CYP2C9CYP2C19BRAFRIPK2 | |
| SCHEMBL856101 | 0.88 | BRAF (0.74) | CYP3A4CYP2C9CYP2C19BRAFRIPK2 | |
| SCHEMBL298051 | 0.88 | CYP2C19 (0.73) | CYP3A4CYP2C9CYP2C19BRAFRIPK2 | |
| SCHEMBL855539 | 0.87 | BRAF (0.65) | CYP3A4CYP2C9CYP2C19BRAFRIPK2 | |
| SCHEMBL297652 | 0.87 | CYP2C19 (0.84) | CYP3A4CYP2C9CYP2C19BRAFRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2023-05-04 | — | — | US | disclosed |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2022-11-08 | — | — | US | disclosed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133044-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CYP3A4 1288/4885CYP2C9 871/4885CYP2C19 1536/4885 |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CYP3A4 1288/4885CYP2C9 871/4885CYP2C19 1536/4885 |
| US-11491154-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CYP3A4 1288/4885CYP2C9 871/4885CYP2C19 1536/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | CYP3A4 3203/4885CYP2C9 4092/4885CYP2C19 4082/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CYP3A4 1288/4885CYP2C9 871/4885CYP2C19 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.